FGF4 Amplification

CI-VAR-00417090Explore in graph →CIViC 5581

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Hepatocellular Carcinoma1
FGF4 Amplification	Sorafenib	Predictive	B	Supports Sensitivity Response	3	submitted	EID13273 In a retrospective analysis of sorafenib-treated hepatocellular carcinoma, FGF3/FGF4 co-amplification was detected in 3 of 10 evaluable tumors from patients with complete or partial responses and in 0… (full text at CIViC) PMID 22890726 · Arao et al., 2013 · Open in CIViC	civic
Malignant Neoplasm1
FGF4 Amplification	Sorafenib	Predictive	D	Supports Sensitivity Response	2	submitted	EID13275 Among 26 cancer cell lines tested for growth inhibition by sorafenib, KYSE220 was the only FGF3/FGF4-amplified cell line and showed marked sorafenib sensitivity, with an IC50 of 0.18 μM. PMID 22890726 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.